Routine Genetic Testing of Germline Breast Cancer Susceptibility ─ Challenges and Opportunities
Information on germline BRCA (g*BRCA*) 1/2 pathogenic or likely pathogenic mutations has predictive value for response to platinating agents and poly(ADP-ribose) polymerase inhibitors (PARPi) and survival outcomes of breast cancer (BC) patients. In the OlympiA trial, the benefits of adjuvant olapari...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2023.17.117 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|